Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...
Bernstein analysts downgraded Liberty Global shares (NASDAQ:LBTYA) to Market Perform from Outperform, adjusting the price target to $12.40 from the previous $24.70. Despite current challenges, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback